Raising the Bar for Accuracy and Cost-Efficiency in Testing for Respiratory Illnesses
COVID-19’s devastating impact on the world has shone a spotlight on the importance of effective diagnostic testing for respiratory illnesses. Canada and UK–based company Gemina Laboratories (CSE:GLAB) is progressing multiple Point-of-Care (PoC) diagnostic products for respiratory diseases, utilizing proprietary chemistry that the company calls “one of the most significant developments in rapid in vitro diagnostics…
(CSE:GLAB)
